Small molecule compounds which specifically target mutant p53 have been developed, including compounds that restore wildtype p53 transcriptional activity and reduce mutant p53 levels, which indicate that target mutant p53 may be an effective strategy for cancer therapy [43]. The gene discussed is TP53; the disease is cancer.